Acute Respiratory Distress Syndrome (ARDS) is a growing and concerning unmet medical need with no effective therapeutic, and a serious medical burden in a world with or without COVID-19.
Network with over 50 other industry pioneers including Ionis Pharmaceuticals, Genentech, Vicore, and AnaMar to hear first-hand how the latest scientific research is innovating and
Day three at the European Society for Medical Oncology 2016 congress belonged to Merck & Co., and may well be seen as a hugely significant day in the future of lung cancer treatment.
AstraZeneca’s Tagrisso (osimertinib) lung cancer drug has met its goal in a late-stage study, potentially paving the way for a full approval in major markets.
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho